Essex Woodlands Health Ventures, Inc.
Q1 2014 13F-HR Holdings
Net value change ($000)
+193,883
(97.5%)
New positions
1
Sold out positions
1
Turnover %
37.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Revance Therapeutics, Inc. | 144,649 | NEW |
| Horizon Therapeutics PLC Com | 42,938 | 101.9% |
| ENDOLOGIX INC /DE/ | 16,001 | 45.0% |
| TCRT | 469 | 4.1% |
| PTNT | 11 | 61.1% |
Top Reduces (Value $000, Stocks/ETFs)
| SOLTA MEDICAL INC | -3,009 | -100.0% |
| Global Cord Blood Corp | -2,749 | -88.8% |
| ABIOMED INC | -2,205 | -2.6% |
| ACURA PHARMACEUTICALS INC | -2,114 | -12.9% |
| MNOV | -106 | -4.2% |
| ECTE | -2 | -5.1% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|